chief, Center of Tobacco Control Reearch, Denmark.
Dr. Finn Edler von Eyben is a renowned specialist in internal medicine and oncology, with significant expertise across Denmark, Norway, and Sweden. He previously served as an administrative consultant at the Department of Internal Medicine, Queen Ingrid’s Hospital, Nuuk, Greenland. Dr. von Eyben is the author of multiple pivotal publications on testis cancer and prostate cancer, particularly in the field of radioligand therapy using PSMA. With a remarkable 12,914 reads and 2,788 citations of his work, he has made substantial contributions to oncological research. He has been invited to present at major international conferences, including those hosted at Innsbruck University, Austria. A prolific researcher, he also edited a theme issue on PSMA and prostate cancer for the International Journal of Molecular Sciences. His work spans over 164 publications, making him a leading figure in modern cancer research.
Profile:
Scopus
Education:
Dr. Finn Edler von Eyben completed his Doctor of Medicine at Southern Sweden in 1985, specializing in tumor markers for testicular cancer. Later, in 2005, he furthered his education at Southern Denmark, continuing his work on tumor markers for testis cancer. His educational foundation has been instrumental in shaping his deep understanding of cancer research, specifically in oncology and internal medicine. The combination of clinical and research-based education has allowed him to make lasting contributions to the medical field, focusing on advanced therapeutic techniques, radioligand therapy, and cancer biomarkers. Throughout his career, Dr. von Eyben has remained committed to advancing medical education through his research, aiming to provide a strong scientific basis for improving clinical outcomes in cancer care.
Experience:
Dr. Finn Edler von Eyben has built an extensive career in internal medicine and oncology across several countries, including Denmark, Norway, and Sweden. His administrative consultant role at the Department of Internal Medicine, Queen Ingrid’s Hospital in Nuuk, Greenland, showcased his leadership abilities in healthcare administration. With over three decades of clinical experience, Dr. von Eyben has been involved in groundbreaking cancer research and therapy, particularly concerning testis and prostate cancers. As a recognized authority, he has been a frequent speaker at international conferences, contributing his insights on PSMA and its role in prostate cancer treatment. His research focus on serum tumor markers and PSMA-based radioligand therapy has been widely influential, with his work being referenced globally. His expertise also extends to serving as the editor of journals and collaborating with fellow researchers, solidifying his position as a thought leader in oncology.
Awards and Honors:
Dr. Finn Edler von Eyben has earned widespread recognition for his outstanding contributions to oncology and internal medicine. His groundbreaking research on testis cancer and prostate cancer therapies has garnered over 2,788 citations, reflecting the high regard in which he is held by the scientific community. He was invited to serve as an editor for the International Journal of Molecular Sciences, where he contributed significantly to the PSMA and prostate cancer theme issue. His career has been marked by numerous invitations to deliver oral presentations at prestigious international conferences on nuclear medicine in oncology, including at Innsbruck University, Austria. Additionally, Dr. von Eyben’s research on radioligand therapy has positioned him at the forefront of the treatment of metastatic prostate cancer. While he has not publicly listed specific formal awards, the high citation index and frequent invitations to speak at conferences underscore the esteem he commands within the field.
Research Focus:
Dr. Finn Edler von Eyben is primarily focused on the treatment and diagnostic aspects of prostate cancer and testicular cancer. His research has greatly contributed to understanding tumor markers, especially in testis cancer, and has advanced the field of PSMA (Prostate-Specific Membrane Antigen)-based radioligand therapy. His notable work includes studies on 177Lu-PSMA-617 radioligand therapy for metastatic prostate cancer, which has revolutionized treatment strategies for castration-resistant prostate cancer. Dr. von Eyben has authored influential systematic reviews on the use of PSMA PET/CT scans in prostate cancer management, offering critical insights into optimal treatment regimens and early detection. Furthermore, his meta-analyses of choline PET/CT imaging for prostate cancer have solidified his role as a leader in nuclear medicine oncology. His work continues to shape clinical practices, focusing on personalized cancer treatments and improving patient outcomes through precision medicine.
Publication Titles:
- 177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer 🏥🔬
- Third-line treatment and (177)Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review 📚🧪
- (177)Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer 🧬⚙️
- Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with (177)Lu-PSMA radioligand therapy ⏳🎯
- (68)Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis 📊🧠
- Meta-analysis of (11)C-choline and (18)F-choline PET/CT for management of patients with prostate cancer 💡💊
- Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review 🧪💉
- Review on the Increasing Role for PSMA-Based Radioligand Therapy in Prostate Cancer 🏆📈